Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: HYP066
MIFTS: 64

Hyperglycemia

Categories: Blood diseases, Metabolic diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Hyperglycemia

About this section

MalaCards integrated aliases for Hyperglycemia:

Name: Hyperglycemia 12 76 29 55 6 43 44 15 73

Classifications:

MalaCards categories:
Global: Metabolic diseases
Anatomical: Blood diseases
See all MalaCards categories (disease lists)
ICD10: 33


External Ids:

Disease Ontology 12 DOID:4195
ICD10 33 R73.9
MeSH 44 D006943
NCIt 50 C26797
SNOMED-CT 68 80394007
UMLS 73 C0020456
Sources

Summaries for Hyperglycemia

About this section
MedlinePlus : 43 Hyperglycemia means high blood sugar or glucose. Glucose comes from the foods you eat. Insulin is a hormone that moves glucose into your cells to give them energy. Hyperglycemia happens when your body doesn't make enough insulin or can't use it the right way. People with diabetes can get hyperglycemia from not eating the right foods or not taking medicines correctly. Other problems that can raise blood sugar include infections, certain medicines, hormone imbalances, or severe illnesses.

MalaCards based summary : Hyperglycemia is related to diabetes mellitus, transient neonatal, 1 and peripheral nervous system disease, and has symptoms including seizures, fever and dyspnea. An important gene associated with Hyperglycemia is MALAT1 (Metastasis Associated Lung Adenocarcinoma Transcript 1), and among its related pathways/superpathways are Developmental Biology and Aldosterone synthesis and secretion. The drugs Zinc and Metformin have been mentioned in the context of this disorder. Affiliated tissues include endothelial, liver and kidney, and related phenotypes are homeostasis/metabolism and growth/size/body region

Wikipedia : 76 Hyperglycemia, or high blood sugar (also spelled hyperglycaemia or hyperglycæmia) is a condition in... more...

Sources

Related Diseases for Hyperglycemia

About this section

Diseases related to Hyperglycemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 409)
# Related Disease Score Top Affiliating Genes
1 diabetes mellitus, transient neonatal, 1 32.7 ABCC8 INS KCNJ11
2 peripheral nervous system disease 32.1 AKR1B1 ALB INS
3 diabetes mellitus, permanent neonatal 32.0 ABCC8 GCK INS KCNJ11 PDX1
4 maturity-onset diabetes of the young, type 2 32.0 GCK HNF1A INS PDX1
5 hyperinsulinism 31.9 ABCC8 GCK IGF1 INS INSR KCNJ11
6 glucose intolerance 31.6 ADIPOQ DPP4 GCG GCK IGF1 INS
7 microvascular complications of diabetes 1 31.6 AKR1B1 IGF1 INS SST
8 diabetes mellitus, insulin-dependent 31.6 AKR1B1 ALB GCG GCK HNF1A IAPP
9 hypoglycemia 30.9 ABCC8 GCG GCK INS INSR KCNJ11
10 lipid metabolism disorder 30.6 ADIPOQ INS LEP PPARG
11 fatty liver disease, nonalcoholic 1 30.5 ADIPOQ INS LEP
12 microvascular complications of diabetes 5 30.4 AKR1B1 ALB IGF1 INS
13 microvascular complications of diabetes 3 30.4 ALB INS MALAT1
14 acromegaly 30.3 IGF1 INS SST
15 gestational diabetes 30.2 ADIPOQ GCK IAPP INS INSR KCNJ11
16 vascular disease 30.2 ADIPOQ ALB INS PPARG
17 arteries, anomalies of 30.2 ADIPOQ ALB INS LEP PPARG
18 diabetic neuropathy 30.1 AKR1B1 INS LEP
19 liver disease 30.0 ADIPOQ ALB INS LEP
20 insulin-like growth factor i 30.0 IGF1 INS INSR LEP SST
21 polycystic ovary syndrome 30.0 IGF1 INS INSR LEP
22 chronic kidney failure 30.0 ADIPOQ ALB IGF1 INS LEP
23 fanconi-bickel syndrome 30.0 ABCC8 INS SLC2A2
24 nonalcoholic fatty liver disease 29.9 ADIPOQ INS LEP PPARG
25 atherosclerosis susceptibility 29.9 ADIPOQ INS PPARG
26 fatty liver disease 29.8 ADIPOQ INS INSR LEP MALAT1
27 nutritional deficiency disease 29.8 ALB IGF1 LEP
28 islet cell tumor 29.8 IAPP INS SST
29 hyperandrogenism 29.7 IGF1 INS INSR
30 nonalcoholic steatohepatitis 29.7 ADIPOQ INS LEP
31 insulinoma 29.6 ABCC8 GCG GCK IAPP INS PDX1
32 uremia 29.6 ALB INS LEP
33 hyperthyroidism 29.6 INS LEP SST
34 abdominal obesity-metabolic syndrome 1 29.6 ADIPOQ INS LEP PPARG
35 monogenic diabetes 29.6 ABCC8 GCK HNF1A INS KCNJ11 PDX1
36 prediabetes syndrome 29.5 ADIPOQ ALB DPP4 GCG INS LEP
37 neonatal diabetes mellitus 29.5 ABCC8 GCK INS KCNJ11 PDX1 SLC2A2
38 maturity-onset diabetes of the young 29.5 ABCC8 DPP4 GCG GCK HNF1A IAPP
39 diabetes mellitus 29.4 ABCC8 ADIPOQ AKR1B1 ALB DPP4 GCG
40 osteoporosis 29.4 ADIPOQ ALB IAPP IGF1 INS LEP
41 diabetes mellitus, noninsulin-dependent 29.1 ABCC8 ADIPOQ AKR1B1 ALB DPP4 GCG
42 body mass index quantitative trait locus 11 29.1 ADIPOQ DPP4 GCG GCK IAPP IGF1
43 maturity-onset diabetes of the young, type 1 28.3 ABCC8 ADIPOQ ALB DPP4 GCG GCK
44 diabetes mellitus, ketosis-prone 11.4
45 diabetes and deafness, maternally inherited 11.3
46 mitochondrial complex iii deficiency, nuclear type 6 11.1
47 pancreas, dorsal, agenesis of 11.0
48 diabetes mellitus, insulin-dependent, 2 10.9
49 renal glucosuria 10.9
50 glycogen storage disease 0, liver 10.9

Graphical network of the top 20 diseases related to Hyperglycemia:



Diseases related to Hyperglycemia
Sources

Symptoms & Phenotypes for Hyperglycemia

About this section

UMLS symptoms related to Hyperglycemia:


seizures, fever, dyspnea, edema, cachexia, vertigo, headache, syncope, cyanosis, icterus, signs and symptoms, signs and symptoms, digestive, hot flushes, symptoms

MGI Mouse Phenotypes related to Hyperglycemia:

46 (show all 13)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.39 ABCC8 ADIPOQ AKR1B1 ALB DPP4 GCK
2 growth/size/body region MP:0005378 10.36 ADIPOQ AKR1B1 DPP4 GCK HNF1A IAPP
3 endocrine/exocrine gland MP:0005379 10.32 ABCC8 ADIPOQ ALB DPP4 GCK HNF1A
4 behavior/neurological MP:0005386 10.25 ADIPOQ AKR1B1 HNF1A INS INSR KCNJ11
5 adipose tissue MP:0005375 10.18 ADIPOQ HNF1A IGF1 INS INSR KCNJ11
6 mortality/aging MP:0010768 10.17 ADIPOQ AKR1B1 ALB GCK HNF1A IGF1
7 digestive/alimentary MP:0005381 10.1 ALB HNF1A INS INSR LEP PDX1
8 liver/biliary system MP:0005370 10.07 ADIPOQ ALB GCK HNF1A INS INSR
9 integument MP:0010771 10.01 ADIPOQ HNF1A IGF1 INS KCNJ11 LEP
10 muscle MP:0005369 10 ADIPOQ ALB HNF1A IGF1 INS INSR
11 no phenotypic analysis MP:0003012 9.76 ABCC8 HNF1A INS KCNJ11 PDX1 PPARG
12 renal/urinary system MP:0005367 9.73 ADIPOQ AKR1B1 ALB GCK HNF1A IGF1
13 skeleton MP:0005390 9.32 ADIPOQ AKR1B1 HNF1A IAPP IGF1 INS
Sources

Drugs & Therapeutics for Hyperglycemia

About this section

Drugs for Hyperglycemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 833)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Zinc Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 7440-66-6
2
Metformin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 657-24-9 14219 4091
3
Glipizide Approved, Investigational Phase 4,Phase 3,Phase 2 29094-61-9 3478
4
Saxagliptin Approved Phase 4,Phase 3,Phase 2,Not Applicable 361442-04-8 11243969
5
Insulin Glargine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 160337-95-1
6
Aripiprazole Approved, Investigational Phase 4,Phase 3 129722-12-9 60795
7
Insulin glulisine Approved Phase 4,Phase 3,Phase 2,Not Applicable 207748-29-6
8
Insulin Detemir Approved Phase 4,Phase 3,Phase 2,Not Applicable 169148-63-4 5311023
9
Acarbose Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 56180-94-0 441184
10
Exenatide Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 141758-74-9 15991534
11
Curcumin Approved, Experimental, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 458-37-7 969516
12
Insulin Aspart Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 116094-23-6 16132418
13
Tramadol Approved, Investigational Phase 4 27203-92-5 33741
14
Parecoxib Approved Phase 4 198470-84-7
15
Celecoxib Approved, Investigational Phase 4,Phase 1,Phase 2 169590-42-5 2662
16
Aspirin Approved, Vet_approved Phase 4,Phase 3,Not Applicable 50-78-2 2244
17
Isosorbide Dinitrate Approved, Investigational Phase 4 87-33-2 6883
18
Nitric Oxide Approved Phase 4,Phase 2,Not Applicable 10102-43-9 145068
19
AT-101 Approved, Investigational Phase 4 90141-22-3, 652-67-5 12597
20
Glyburide Approved Phase 4,Phase 3,Phase 2,Not Applicable 10238-21-8 3488
21
Ramipril Approved Phase 4,Phase 3 87333-19-5 5362129
22
Hydrochlorothiazide Approved, Vet_approved Phase 4,Phase 3,Phase 2 58-93-5 3639
23
Simvastatin Approved Phase 4,Phase 3,Phase 2,Not Applicable 79902-63-9 54454
24
Amlodipine Approved Phase 4 88150-42-9 2162
25
Doxazosin Approved Phase 4 74191-85-8 3157
26
Irbesartan Approved, Investigational Phase 4 138402-11-6 3749
27
Atenolol Approved Phase 4 29122-68-7 2249
28
Furosemide Approved, Vet_approved Phase 4,Phase 2 54-31-9 3440
29
Clonidine Approved Phase 4 4205-90-7 2803
30
Angiotensin II Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 11128-99-7, 68521-88-0, 4474-91-3 172198 65143
31
Valsartan Approved, Investigational Phase 4,Phase 1,Phase 2 137862-53-4 60846
32
Hydrocortisone Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 50-23-7 5754
33
Hydrocortisone acetate Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 50-03-3
34
Moxonidine Approved, Investigational Phase 4 75438-57-2 4810
35
Prednisolone phosphate Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 302-25-0
36
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-24-8 5755
37
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 83-43-2 6741
38
Methylprednisolone hemisuccinate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 2921-57-5
39
Ethanol Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 64-17-5 702
40
Rosiglitazone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 122320-73-4 77999
41
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 94-09-7, 1994-09-7 2337
42
Insulin Lispro Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 133107-64-9
43 tannic acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
44
Liraglutide Approved Phase 4,Phase 3,Phase 2,Not Applicable 204656-20-2 44147092
45
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-02-2 5743
46
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1177-87-3
47
Nicotinamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 98-92-0 936
48
Racepinephrine Approved Phase 4,Phase 3,Not Applicable 329-65-7 838
49
Epinephrine Approved, Vet_approved Phase 4,Phase 3,Not Applicable 51-43-4 5816
50
Tacrolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 104987-11-3 445643 439492

Interventional clinical trials:

(show top 50) (show all 2099)
# Name Status NCT ID Phase Drugs
1 The Therapeutic Effects of Insulin and Berberine on Stress Hyperglycemia Unknown status NCT02806999 Phase 4 Berberine; Insulin;Insulin
2 Outpatient Discharge Therapy With Saxagliptin+MetforminXR vs GlipizideXL for Type 2 Diabetes With Severe Hyperglycemia Unknown status NCT01267448 Phase 4 Glipizide XL;Saxagliptin + Metformin XR;Metformin XR
3 Intensive Versus Nonintensive Insulin Therapy for Hyperglycemia After Traumatic Brain Injury Unknown status NCT02161055 Phase 4 Insulin
4 Effect of Acute Hyperglycemia on Renal Tissue Oxygenation Unknown status NCT02346149 Phase 4
5 ß-Cell Function and Glycemic Control in Newly Diagnosed Type 2 Diabetic Patients With Moderate Hyperglycemia Unknown status NCT01717911 Phase 4 Insulin;Metformin;Sitagliptin
6 Reversal of Antipsychotic-Induced Hyperprolactinemia, Weight Gain, Hyperglycemia and Dyslipidemia Unknown status NCT00541554 Phase 4 Abilify (aripiprazole)
7 Arterial Catheter to Monitor Glycemia Unknown status NCT01176279 Phase 4
8 Treatment With Continuous Sub-cutaneous Insulin Infusion Via a Portable Pump Versus Discontinuous Insulin Infusion Via Multiple-injections in Type 2 Diabetes Unknown status NCT02048189 Phase 4 LEVEMIR;APIDRA
9 A Trial Comparing SGC and Conventional Empiric Treatment for Glucose Control in Critically Ill Patients With Mechanical Ventilation in ICU Unknown status NCT02491346 Phase 4
10 Impact of Acarbose on Abnormal Glucose Regulation in Patients With Coronary Artery Disease (AAA Trial) Unknown status NCT00858676 Phase 4 acarbose
11 The Effects of Short-Term Exenatide Therapy in Newly Diagnosed Type 2 Diabetic Patients Unknown status NCT01270191 Phase 4 Exenatide;Humulin-N
12 Curcumin for Type 2 Diabetic Patients Unknown status NCT01052597 Phase 4 curcumin
13 Insulin Infusion Diabetes Ulcer Unknown status NCT00700154 Phase 4
14 Effect of COX-2 Selective Inhibitors on Postoperative Insulin Resistance After Gastrointestinal Laparoscopic Surgery Unknown status NCT01930318 Phase 4 parecoxib
15 Type 2 Diabetes Mellitus and Atherosclerosis Unknown status NCT01250340 Phase 4 Aspirin;Placebo
16 Various Insulin Regimens for Diabetic Inpatients With Cirrhosis Trial Unknown status NCT01143948 Phase 4 Glargine & Glulisine;Regular insulin;NPH & regular insulin
17 Chronic Treatment With Benfotiamine Restores Endothelial Function in People With Type 2 Diabetes Mellitus Unknown status NCT00446810 Phase 4 Benfotiamine;Placebo
18 Influence of Nitrates on Bone Remodeling and Endothelial Function in Patients With Type 2 Diabetes Mellitus Unknown status NCT02011620 Phase 4
19 Assessment of Dapagliflozin Effect on Diabetic Endothelial Dysfunction of Brachial Artery Unknown status NCT02919345 Phase 4 Dapagliflozin 10 mg;Glibenclamide 5 mg
20 Exenatide and Brown Adipose Tissue Unknown status NCT03002675 Phase 4 Bydureon
21 Substitution of First Phase Insulin Response in Patient With Type 2 Diabetes. Unknown status NCT00254085 Phase 4 Insulin Aspart
22 Nephropathy In Type 2 Diabetes and Cardio-renal Events Unknown status NCT00535925 Phase 4 current therapy;irbesartan;ramipril;hydrochlorothiazide;furosemide;amlodipine;atenolol;doxazosin;clonidine;insulin;simvastatin;fibrate;erythropoietin;aspirin
23 Effects of Valsartan and Aliskiren on Hemostatic Indices in Hypertensive Diabetics Unknown status NCT01095822 Phase 4 Aliskiren + Valsartan
24 Insulin NovoRapid Versus Actrapid in Treatment of Type 1 Diabetic Patients During Daily Adjustment of Insulin Dose Unknown status NCT00145353 Phase 4 Insulin NovoRapid versus Actrapid
25 Efficacy of Acarbose on Intestinal Microbiome and Incretins of Type 2 Diabetes Unknown status NCT01758471 Phase 4 Glipizide;Acarbose
26 Study of the Effect of Moxonidine and Diet on Sympathetic Functions in Young Adults With Obesity Unknown status NCT01180231 Phase 4 Moxonidine (Physiotens)
27 Bone Turnover in Type 2 Diabetes Patients Unknown status NCT00732121 Phase 4 Sitagliptin;Placebo
28 TReatment by Insulin Continuous Infusion in Type 2 DIAbetes Unknown status NCT01889914 Phase 4 2 different procedures of administration of insulin
29 Comparison Study of Insulin Glargine and NPH Insulin Unknown status NCT01854723 Phase 4 Switching to NPH insulin;Continuation of insulin glargine
30 Effect of SGLT-2 Inhibitor Dapagliflozin on Glycemic Variability in Patients With Diabetes Mellitus Type 2 Unknown status NCT02719756 Phase 4 Metformin;Dapagliflozin;Metformin up-titration
31 6-Methyl-Prednisolone for Multiple Organ Dysfunction Syndrome Unknown status NCT00127985 Phase 4 6-methyl-prednisolone
32 Intensity of Exercise and Glucose Metabolism Unknown status NCT01649219 Phase 4
33 Curcumin Therapy in Patients With Impaired Glucose Tolerance and Insulin Resistance Unknown status NCT01052025 Phase 4 Curcumin
34 Effect of Metadoxine on Oxidative Stress in Non-alcoholic Hepatic Steatosis Unknown status NCT02051842 Phase 4 Metadoxine
35 Effect of Saxagliptin on Pre-Diabetes Mellitus and Obesity Unknown status NCT01960205 Phase 4 Saxagliptin;saxagliptin;metformin
36 Rosiglitazone Therapy In The Prevention Of Coronary Artery Disease In Patients With Impaired Glucose Tolerance Unknown status NCT00733174 Phase 4 Rosiglitazone;Placebo
37 Sitagliptin for Hyperglycemia in Patients With T2DM Undergoing Cardiac Surgery Completed NCT02556918 Phase 4 Sitagliptin;Placebo;Regular Human Insulin;Insulin glargine;Supplemental insulin (Insulin lispro);Supplemental insulin (Insulin aspart)
38 Hyperglycemia and Effects of Daily 100 mg Versus 200 mg of Hydrocortisone Therapy in Patients With Septic Shock Completed NCT02266264 Phase 4 Hydrocortisone
39 Sitagliptin in Non-Diabetic Patients Undergoing General Surgery Completed NCT02741687 Phase 4 Sitagliptin;Placebo;Supplemental insulin (insulin lispro);Supplemental insulin (insulin aspart);Long acting basal insulin (insulin detemir);Long acting basal insulin (insulin glargine)
40 Glucose Control for Glucocorticoid Induced Hyperglycemia During Chemotherapy Completed NCT02155374 Phase 4 Sliding scale insulin;Intermediate acting insulin;Glucose lowering medication;Chemotherapy
41 Hospital Insulin Protocol Aims for Glucose Control in Corticosteroid-induced Hyperglycemia Completed NCT01184014 Phase 4 NPH insulin plus Complete Insulin Orders;Complete Insulin Orders
42 Sitagliptin in Non-Diabetic Patients Undergoing Cardiac Surgery Completed NCT02443402 Phase 4 Sitagliptin;Placebo;Regular Human Insulin;Insulin glargine;Supplemental insulin (Insulin lispro);Supplemental insulin (Insulin aspart)
43 NPH and Regular Insulin in the Treatment of Inpatient Hyperglycemia: Comparison of 3 Basal-bolus Regimens Completed NCT02758522 Phase 4 Once-daily Insulin;Twice-daily Insulin;Triple-daily Insulin
44 The Management of Glucocorticoid-Induced Hyperglycemia in Hospitalized Patients Completed NCT01810952 Phase 4 Glargine insulin;Lispro insulin;NPH Insulin
45 Study of Management of Pasireotide-induced Hyperglycemia in Adult Patients With Cushing's Disease or Acromegaly Completed NCT02060383 Phase 4 Pasireotide s.c.;Sitagliptin;Liraglutide;Insulin;Pasireotide LAR;Metformin
46 Intensive Insulin Therapy in Non-diabetic Patients With Acute Myocardial Infarction and Hyperglycaemia Completed NCT00362778 Phase 4 Insulin
47 Effect of Low-Dose Dexamethasone on the Incidence of Hyperglycemia Following Surgery Completed NCT01545700 Phase 4 Control-saline;Dexamethasone 4 mg;Dexamethasone 8 mg;Control saline;Dexamethasone 4 mg;Dexamethasone 8 mg
48 Study of a Model-based Approach to Blood Glucose Control in Very-low-birthweight Neonates Completed NCT01419873 Phase 4 Actrapid Human Insulin
49 Hyperglycemia and Cardiovascular Outcomes With Type 2 Diabetes Completed NCT00191282 Phase 4 Insulin lispro;Human insulin isophane suspension (NPH);Insulin glargine;Human insulin isophane suspension;Human insulin 30/70
50 A Study of Postprandial Hyperglycemia in Participants With Type 2 Diabetes Completed NCT01159938 Phase 4 Lispro

Search NIH Clinical Center for Hyperglycemia

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: hyperglycemia

Sources

Genetic Tests for Hyperglycemia

About this section

Genetic tests related to Hyperglycemia:

# Genetic test Affiliating Genes
1 Hyperglycemia 29
Sources

Anatomical Context for Hyperglycemia

About this section

MalaCards organs/tissues related to Hyperglycemia:

41
Endothelial, Liver, Kidney, Brain, Heart, Testes, Pancreas
Sources

Publications for Hyperglycemia

About this section

Articles related to Hyperglycemia:

(show top 50) (show all 2392)
# Title Authors Year
1
Taxifolin prevents postprandial hyperglycemia by regulating the activity of α-amylase: Evidence from an in vivo and in silico studies. ( 30191607 )
2019
2
Pathological Perturbations in Diabetic Retinopathy: Hyperglycemia, AGEs, Oxidative Stress and Inflammatory Pathways. ( 30264677 )
2019
3
Brain-derived neurotrophic factor inhibits hyperglycemia-induced apoptosis and downregulation of synaptic plasticity-related proteins in hippocampal neurons via the PI3K/Akt pathway. ( 30365051 )
2019
4
Paternal hyperglycemia induces transgenerational inheritance of susceptibility to hepatic steatosis in rats involving altered methylation on Pparα promoter. ( 30404040 )
2019
5
Dairy milk proteins attenuate hyperglycemia-induced impairments in vascular endothelial function in adults with prediabetes by limiting increases in glycemia and oxidative stress that reduce nitric oxide bioavailability. ( 30412905 )
2019
6
A review of the molecular mechanisms of hyperglycemia-induced free radical generation leading to oxidative stress. ( 30146696 )
2019
7
Perioperative Management of Hyperglycemia and Diabetes in Cardiac Surgery Patients. ( 29407052 )
2018
8
Baicalin administration attenuates hyperglycemia-induced malformation of cardiovascular system. ( 29445081 )
2018
9
Ginger alleviates hyperglycemia-induced oxidative stress, inflammation and apoptosis and protects rats against diabetic nephropathy. ( 29966984 )
2018
10
Diastolic dysfunction is more apparent in STZ-induced diabetic female mice, despite less pronounced hyperglycemia. ( 29402990 )
2018
11
Incidence and management of postoperative hyperglycemia in patients undergoing insulinoma resection. ( 29923016 )
2018
12
Hyperglycemia Alters the Structure and Hemodynamics of the Developing Embryonic Heart. ( 29439517 )
2018
13
Long-term reduction in hyperglycemia in advanced type 1 diabetes: the value of induced aerobic glycolysis with BCG vaccinations. ( 29951281 )
2018
14
Contribution of BHG and PPHG to Overall Hyperglycemia in T2DM Patients Treated with LM25 and LM50: Post Hoc Analysis of a Randomized Crossover Trial. ( 29951978 )
2018
15
Management of hyperglycemia during and in the immediate follow-up of acute coronary syndrome. ( 29910582 )
2018
16
Correlation of hyperglycemia with mortality after acute ischemic stroke. ( 29399044 )
2018
17
Reduced Efficacy of Insulin Detemir in Controlling Hyperglycemia during Pregnancy: An Interesting Case Report. ( 29911051 )
2018
18
Survivin regulated by autophagy mediates hyperglycemia-induced vascular endothelial cell dysfunction. ( 29391151 )
2018
19
Maternal vitamin D and neonatal anthropometrics and markers of neonatal glycaemia: Belfast Hyperglycemia and Adverse Pregnancy Outcome (HAPO) study. ( 29936925 )
2018
20
Impact of varying levels of hyperglycemia on clinicoradiographic outcomes after endovascular reperfusion treatment. ( 29959399 )
2018
21
ULK1-regulated autophagy: A mechanism in cellular protection for ALDH2 against hyperglycemia. ( 29128638 )
2018
22
Hyperglycemia and diabetes mellitus are related to vestibular organs dysfunction: truth or suggestion? A literature review. ( 29936650 )
2018
23
Could the stress hyperglycemia ratio predict the clinical outcomes of coronary artery disease patients after percutaneous coronary intervention? ( 29407118 )
2018
24
Individuals with Type 1 and Type 2 Diabetes Mellitus Trade Increased Hyperglycemia for Decreased Hypoglycemia When Glycemic Variability is not Improved. ( 29164512 )
2018
25
Publisher Correction: Targeting hepatic glutaminase activity to ameliorate hyperglycemia. ( 29895835 )
2018
26
Hyperglycemia attenuates the association between telomere length and age in Ukrainian population. ( 29958997 )
2018
27
Melatonin attenuates smoking-induced hyperglycemia via preserving insulin secretion and hepatic glycogen synthesis in rats. ( 29437243 )
2018
28
Hyperglycemia-Driven Neuroinflammation Compromises BBB Leading to Memory Loss in Both Diabetes Mellitus (DM) Type 1 and Type 2 Mouse Models. ( 29974394 )
2018
29
Remission of hyperglycemia after withdrawal of oral antidiabetic drugs in Japanese patients with early stage of type 2 diabetes. ( 29406607 )
2018
30
PPAR-I+ Agonist Improves Hyperglycemia-Induced Oxidative Stress in Pancreatic Cells by Potentiating Antioxidant Defense System. ( 29433142 )
2018
31
Longitudinal study of body mass index, dyslipidemia, hyperglycemia, and hypertension in 60,000 men and women in Sweden and Austria. ( 29897925 )
2018
32
Hyperglycemia induced testicular damage in type 2 diabetes mellitus rats exhibiting microcirculation impairments associated with vascular endothelial growth factor decreased via PI3K/Akt pathway. ( 29435181 )
2018
33
Hyperglycemia is associated with cardiac complications in elderly nondiabetic patients receiving total parenteral nutrition. ( 29419661 )
2018
34
Hyperglycemia decreases anti-cancer efficiency of Adriamycin via AMPK pathway. ( 29941677 )
2018
35
Kaempferol attenuates hyperglycemia-induced cardiac injuries by inhibiting inflammatory responses and oxidative stress. ( 29392616 )
2018
36
Abdominal circumference profiles of macrosomic infants born to mothers with or without hyperglycemia in China. ( 29886780 )
2018
37
Hyperglycemia induces epithelial-mesenchymal transition in the lungs of experimental diabetes mellitus. ( 29934127 )
2018
38
Effect of Hyperglycemia on Purinergic and Nitrergic Inhibitory Neuromuscular Transmission in the Antrum of the Stomach: Implications for Fast Gastric Emptying. ( 29410956 )
2018
39
Pulsatile hyperglycemia increases insulin secretion but not pancreatic I^-cell mass in intrauterine growth-restricted fetal sheep. ( 29973299 )
2018
40
Dopaminergic neurodegeneration in a rat model of long-term hyperglycemia: preferential degeneration of the nigrostriatal motor pathway. ( 29890391 )
2018
41
Short and Sweet: A commentary on short sleep duration and hyperglycemia in pregnancy. ( 29887257 )
2018
42
Perspectives on diagnostic strategies for hyperglycemia in pregnancy - dealing with the barriers and challenges in South Asia. ( 29408685 )
2018
43
Effect of high glucose on cytokine production by human peripheral blood immune cells and type I interferon signaling in monocytes: Implications for the role of hyperglycemia in the diabetes inflammatory process and host defense against infection. ( 29894743 )
2018
44
The association between famine exposure in early life and type 2 diabetes and hyperglycemia in adulthood: results from the China health and retirement longitudinal study (CHARLS). ( 29451367 )
2018
45
Hyperglycemia in Acute Coronary Syndromes: From Mechanisms to Prognostic Implications. ( 29407051 )
2018
46
Hyperglycemia-induced mouse trophoblast spreading is mediated by reactive oxygen species. ( 29392783 )
2018
47
NAP counteracts hyperglycemia/hypoxia induced retinal pigment epithelial barrier breakdown through modulation of HIFs and VEGF expression. ( 28436035 )
2018
48
Feasibility and safety of using an automated decision support system for insulin therapy in the treatment of steroid-induced hyperglycemia in patients with acute graft-versus-host disease: A randomized trial. ( 30144380 )
2018
49
Hyperglycemia and risk of ventricular tachycardia among patients hospitalized with acute myocardial infarction. ( 30340589 )
2018
50
Hyperglycemia Promotes Chemoresistance Through the Reduction of the Mitochondrial DNA Damage, the Bax/Bcl-2 and Bax/Bcl-XL Ratio, and the Cells in Sub-G1 Phase Due to Antitumoral Drugs Induced-Cytotoxicity in Human Colon Adenocarcinoma Cells. ( 30150934 )
2018
Sources

Variations for Hyperglycemia

About this section

ClinVar genetic disease variations for Hyperglycemia:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 KLF11 NM_003597.4(KLF11): c.23G> A (p.Gly8Asp) single nucleotide variant Uncertain significance GRCh37 Chromosome 2, 10183866: 10183866
2 KLF11 NM_003597.4(KLF11): c.23G> A (p.Gly8Asp) single nucleotide variant Uncertain significance GRCh38 Chromosome 2, 10043739: 10043739

Copy number variations for Hyperglycemia from CNVD:

7
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 44162 10 52900000 70600000 Copy number TFAM Hyperglycemia
Sources

Expression for Hyperglycemia

About this section
Search GEO for disease gene expression data for Hyperglycemia.